Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00693329 · ClinicalTrials.gov registry record
Neutrophil Gelatinase-associated Lipcalin(NGAL): A Novel Blood Marker for Determining the Risk of Developing Contrast-Induced Nephopathy
A clinical trial of Cardiovascular Surgery With Coronary Angiography, sponsored by Abbott RDx Cardiometabolic.
- Completed
- Registry status
- 260
- Enrollment target
- 3
- Study locations
NCT00693329 is a study of Cardiovascular Surgery With Coronary Angiography that has completed, run by Abbott RDx Cardiometabolic. The registered enrollment target is 260 participants. The trial reports 3 study locations across 1 state.
The verdict
NCT00693329, a study of Cardiovascular Surgery With Coronary Angiography, has completed, sponsored by Abbott RDx Cardiometabolic.
- COMPLETED
- Registry status
- 260 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-center clinical study designed to assess the performance of the Triage NGAL test as an aid in the early risk assessment for contrast-induced nephropathy (CIN). Approximately 260 adults at risk for CIN undergoing intra-arterial angiography involving administration of iodinated contrast agent(s) will be enrolled.
Conditions Studied
Study Locations (3)
Michigan
- Cardiac and Vascular Research Center of Northern Michigan - Petoskey
- Providence Hospital - Providence
- William Beaumont Hospital - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00693329
The ClinicalTrials.gov registry entry for NCT00693329 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott RDx Cardiometabolic, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiovascular Surgery With Coronary Angiography appearing as the primary indexed condition, and to 0 interventions.
NCT00693329 reports 3 study locations spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT00693329 about?
NCT00693329 is a clinical study titled "Neutrophil Gelatinase-associated Lipcalin(NGAL): A Novel Blood Marker for Determining the Risk of Developing Contrast-Induced Nephopathy". This is a multi-center clinical study designed to assess the performance of the Triage NGAL test as an aid in the early risk assessment for contrast-induced nephropathy (CIN). Approximately 260 adults at risk for CIN undergoing intra-arterial angiography involving administration of iodinated contras...
What is the current status of trial NCT00693329?
This trial is currently completed. The enrollment target is 260 participants. The study started on 2008-03. Estimated completion is 2009-12.
What conditions does trial NCT00693329 study?
This clinical trial studies the following conditions: Cardiovascular Surgery With Coronary Angiography.
Who is sponsoring clinical trial NCT00693329?
This trial is sponsored by Abbott RDx Cardiometabolic, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00693329 being conducted?
This trial has 3 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.